Review Article

The Function and Role of the Th17/Treg Cell Balance in Inflammatory Bowel Disease

Jun-bin Yan, Min-min Luo, Zhi-yun Chen, and Bei-hui He

The Second Central Laboratory, Key Laboratory of Integrative Chinese and Western Medicine for the Diagnosis and Treatment of Circulatory Diseases of Zhejiang Province, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China

Correspondence should be addressed to Bei-hui He; graf303@sina.com

Received 13 August 2020; Revised 28 September 2020; Accepted 9 December 2020; Published 15 December 2020

Academic Editor: Jie Tian

Copyright © 2020 Jun-bin Yan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Inflammatory bowel disease (IBD) is a chronic, inflammatory, and autoimmune disorder. The pathogenesis of IBD is not yet clear. Studies have shown that the imbalance between T helper 17 (Th17) and regulatory T (Treg) cells, which differentiate from CD4+ T cells, contributes to IBD. Th17 cells promote tissue inflammation, and Treg cells suppress autoimmunity in IBD. Therefore, Th17/Treg cell balance is crucial. Some regulatory factors affecting the production and maintenance of these cells are also important for the proper regulation of the Th17/Treg balance; these factors include T cell receptor (TCR) signaling, costimulatory signals, cytokine signaling, bile acid metabolites, and the intestinal microbiota. This article focuses on our understanding of the function and role of the balance between Th17/Treg cells in IBD and these regulatory factors and their clinical significance in IBD.

1. Introduction

IBD is a disorder that involves chronic and recurrent nonspecific intestinal inflammation with unknown aetiology and pathogenesis. The types of IBD include ulcerative colitis (UC), which can cause long-lasting inflammation and ulcers in the colon, and Crohn’s disease (CD), which is characterized by inflammation of the lining of the digestive tract, which can spread into other tissues [1]. IBD can lead to life-threatening complications, including primary sclerosing cholangitis, blood clots, and even colon cancer [2].

The pathogenesis of IBD is still unclear, and the aetiology of IBD may include the host immune system, genetic variability, and environmental factors [3]. In recent years, it has been found that the abnormal intestinal mucosal immune system plays a crucial role in the occurrence, development, and prognosis of IBD, in which the influence of the imbalance in Th17 and Treg cells has been confirmed by previous studies [4, 5]. Multiple factors are involved in the Th17 and Treg cell balance and mainly include TCR signaling, costimulatory signals, cytokine signaling, bile acid metabolites, and the intestinal microbiota.

This paper will discuss the roles of these factors in regulating the balance in Th17/Treg cells and their subsequent influence of IBD, which will provide new perspectives for the treatment of IBD.

2. Th17 Cells

As a CD4+ T cell subset, Th17 cells play dual roles in the pathogenesis of IBD (mainly a proinflammatory role) [6]. Th17 cells can not only protect the intestinal mucosa by keeping the balance of the immune microenvironment but also exacerbate the intestinal inflammatory response through proinflammatory cytokines. The differentiation process of Th17 cells can be divided into three stages: IL-6 and TGF-β initiate the differentiation of Th17 cells, IL-21 expands the differentiation state of Th17 cells, and IL-23 maintains the stable maturation of Th17 cells during the later stage of differentiation [7].
3. Treg Cells

Treg cells are a subset of CD4+ T cells that play a negative immunomodulatory role and play an essential role in maintaining immune tolerance and balance. Considerable evidence indicates that Treg cells in the intestinal microenvironment contribute to the pathogenesis of IBD [8]. Treg cells mainly participate in various immune diseases by secreting anti-inflammatory cytokines, such as TGF-β and IL-10, suppressing the activity of immune cells and thereby controlling inflammation [9]. According to their origin, natural regulatory T (nTreg) cells are primarily generated in the thymus (iTreg) or generated extrathymically in the periphery (pTreg) in vivo. On the other hand, Tregs generated from naive T cells in vitro, in the presence of transforming growth factor-β (TGF-β) and IL-2, are called induced Treg (iTreg) cells. Murine studies have shown that iTreg cells exhibit strong lineage fidelity, whereas pTreg cells can revert into conventional CD4+ T cells [10]. Tregs are characterized by forkhead box protein P3 (Foxp3) expression, and Helios is a marker of iTreg for distinguishing Treg cells from pTreg cells [11].

4. Th17/Treg Cell Balance in IBD

Th17 and Treg cells are related through differentiation and in the inhibition of function. They share a common signal pathway mediated by TGF-β. Studies have shown that in the presence of IL-6 or IL-21 (with TGF-β), naive CD4+ T cells differentiate into Th17 cells; however, in the absence of pro-inflammatory cytokines, naive CD4+ T cells differentiate into Treg cells [12]. Once this balance is broken, a number of autoimmune diseases, including IBD, will occur.

Th17 cells play an important role in the pathogenesis of IBD. Studies have shown that compared with those of healthy controls, Th17 cells infiltrate the intestinal mucosa of IBD patients, and the amount of the cytokine IL-17 that is specifically secreted by Th17 cells increases [13]. In the UC mouse model, Th17 cells in the peripheral blood of mice also increased [14].

Compared with Th17 cells, Treg cells not only suppress the occurrence of autoimmune diseases but also control intestinal inflammation. In the UC mouse model, Treg cells in the peripheral blood of mice decreased [15], and by increasing the secretion of IL-10 and TGF-β, the symptoms of diarrhea in mice were significantly improved [16]. Therefore, Treg cells may be regulated by IL-10, TGF-β, and other anti-inflammatory factors that are secreted to suppress the intestinal inflammation cascade and amplify the response, thereby improving the clinical symptoms of IBD. Relevant clinical observations and animal experiments have shown that Treg cells and their inhibitory mechanism are essential for inhibiting spontaneous intestinal inflammation [17]. Therefore, Treg cell deficiency may be the central link in the pathogenesis of IBD.

The regulation of Th17/Treg cell balance is prospective to be a new target for the treatment of IBD. The vitamin A metabolite such as retinoic acid (RA) is the main regulator of the TGF-β-dependent immune response, which can prevent IL-6 from inducing proinflammatory Th17 cells and differentiate into anti-inflammatory Treg cells. RA may be helpful in the treatment of IBD [18].

5. Factors Affecting the Th17/Treg Cell Balance in IBD

5.1. TCR and Costimulatory Signals. The TCR can bind to peptide-major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells (APCs). In the immune system, the TCR recognizes antigens, transmits signals, and determines the differentiation of T cells [19]. When the TCR-peptide-MHC is on the surface of APCs with the coreceptor CD4 or CD8, it activates the tyrosine-based activation motif (ITAM) at the end of the CD3 chain. Finally, TCR activation enables the differentiation of naive CD4+ T cells [20].

TCR signal strength could alter the balance of Th17 and Treg cells [21]. IL-2 inducible T cell kinase (ITK), a critical regulator of intracellular signaling downstream of the TCR, positively regulates the differentiation of Th17 and negatively regulates the differentiation of Treg cells [22]. Studies have shown that attenuated TCR signaling in ITK/-/- cells induced immature T lymphocytes to preferentially differentiate into Treg cells but not Th17 cells by inhibiting the Akt/mTOR signaling pathway [23]. Attenuated TCR signals caused by mutations in particular components of the TCR signaling pathway, such as Zap70 [23], DAGs [24], Raf [25], and NF-xB [26], will affect the development of Treg cells [27]. Studies have shown that attenuated TCR signals did not only promote the growth of iTreg cells but also inhibit [28], such as naïve T cells require weak TCR signals to differentiate into Treg cells [29]. Additionally, aminocyl tRNA synthetase (ARS)-interacting multifunctional protein 1 (AIMP1) affects the balance of Th17 and Treg cells directly by downregulating TCR signal complex formation and inducing CD4+ T cells differentiate into Treg cells [30]. In contrast, the differentiation of Th17 cells was not now affected [29]. Bach2, a transcription factor of downstream of TCR signaling, balances TCR signal-induced transcriptional activity of IRF4 to maintain homeostasis of iTreg and pTreg cells and shapes the balance of Th17/Treg cells [31].

The TCR is not sufficient for the complete activation and differentiation of T cells. TCR stimulation in the absence of costimulation will induce anergy or cell apoptosis instead of activation [32]. Therefore, secondary signals are required. Costimulatory signals produced by the interaction of different costimulatory molecules and their ligands could accelerate the differentiation of naïve T cells [33]. CD28 is a costimulatory molecule expressed on the surface of T lymphocytes and plays a crucial role in the activation of T cells. Studies have shown that the costimulatory molecule CD28 participates in the induction of Th17 differentiation [34]. CD28 can also, together with the TCR, upregulate the expression of OX40 [35]. The T cell costimulatory molecule OX40 and its cognate ligand OX40L collectively play an essential role in keeping the growth of Th17 and Treg cells. It was found that the activation of OX40 enhanced Th17 function while blocking OX40L decreased Treg proliferation [36].
Table 1: The role of cytokines in Th17/Treg balance.

| Cytokines | Mechanism | Changes |
|-----------|-----------|---------|
| TGF-β     | The stimulation of naïve CD4+ T cells with TGF-β induces SMAD2 and SMAD3, which in turn activate the transcription factor Foxp3 | Treg↑ [45, 46] |
| HIF-1α    | HIF-1α promotes Th17 differentiation by directly inducing RORγt transcription. Also, HIF-1α inhibits Treg differentiation through an active process that targets Foxp3 protein for degradation | Th17↑ [42] |
| IL-2      | IL-2 phosphorylates STAT5, which binds to the Foxp3 locus and upregulates the expression of Foxp3 | Treg↑ [54] |
| IL-6      | IL-6 drives naïve CD4+ T cells to differentiate into Th17 by phosphorylating TβRα/βγ, which then upregulates the expression of Foxp3 by activating STAT5 and inhibits the differentiation of Th17 by reducing the secretion of IL-17 | Th17↑ [42] |
| IL-15     | IL-15 upregulates the expression of Foxp3 by activating STAT5 and inhibits the differentiation of Th17 by reducing the secretion of IL-17 | Treg↑ [55] |
| IL-18     | IL-18 inhibits the MyD88-dependent downstream signal IL-1R, which in turn reduces the differentiation of Th17 | Treg↑ [53] |
| IL-21     | IL-21 induces the differentiation of Th17 by activating STAT3, which then upregulate the expression of RORγt | Th17↑ [51, 52] |
| IL-23     | IL-23 maintains the differentiation of Th17 by enhancing the transcription of Th17 signature cytokines, such as RORγt | Th17↑ [50] |

37]. However, the effect of costimulatory signals on the balance of Th17 and Treg cells is mainly realized by acting as the second signals of TCR signals.

There are also some coinhibitory receptors, which inhibit the strength of TCR signals. Among them, cytotoxic T lymphocyte antigen 4 (CTLA4) has received much attention. CTLA4, a highly homologous receptor of CD28, competes with CD28 for the same ligands (CD80 and CD86). CTLA4 binds the ligands with a high affinity allowing CTLA4 to inhibit T cell responses by competing with CD28 [38]. Studies have shown that CD28 and CTLA4 have opposing influences on T cell stimulation, and CD28 provides an activating signal, while CTLA4 delivers an inhibitory signal [39]. Costimulatory and coinhibitory signals coexist TCR signals in regulating the balance of Th17 and Treg cells.

5.2. Cytokines. Cytokines, small peptides secreted by cells in autocrine and paracrine manners, are the most potent determinants of the fate of T cells. It has been found that the cytokines, which involve in regulating the balance of Th17 cells and Treg cells, are mainly inflammation cytokines, mainly including transforming growth factor-β (TGF-β), IL-2, IL-6, IL-15, IL-18, IL-2, and IL-23 [40].

TGF-β acts on the naïve CD4+ T cells to induce the development of Th17 cells and Treg cells, while IL-6 induces specific genes in Th17 cells by phosphorylating STAT3, which drives the upregulation of Th17-specific genes, such as ROReγt, IL-17, and IL-23 receptor (IL-23R) [41, 42]. In patients with IBD, TGF-β is highly expressed, but TGF-β-mediated immunosuppression is significantly impaired. Researchers have found that this effect is related to Smad7, an intracellular protein that binds to the receptors of TGF-β and inhibits the Smad-dependent signal transduction driven by TGF-β1 [43]. Silencing Smad7 with specific antisense oligodeoxynucleotides can restore TGF-β1/Smad signal transduction, downregulate the expression of inflammatory cytokines, and improve experimental UC in mice [44]. The stimulation of naïve CD4+ T cells with TGF-β induces SMAD2 and SMAD3, which in turn activate the transcription factor Foxp3, which could facilitate the differentiation of Treg cells [45, 46]. Unlike IL-6 and TGF-β, IL-23 does not directly induce Th17 cell differentiation because of the absence of IL-23R in naïve T cells [47]. In mice, T cell receptors engage and bind with specific cytokines, such as TGF-β, inducing a network of transcription factors, of which retinoid-related orphan receptor-yt (ROReγt) is the primary regulator and promotes IL-23R expression [48]. IL-23 could thus activate signal transducer and activator of transcription 3 (STAT3) by interacting with IL-23R [49], which promotes the expression of IL-23R and ROReγt, supporting a positive feedback loop that stabilizes the gene expression required for the activation of Th17 cells [50]. IL-21 can also induce the differentiation of Th17 by activating STAT3, which then upregulates the expression of RORγt [51, 52]. IL-18 inhibits the MyD88-dependent downstream signal IL-1R, which in turn reduces the differentiation of Th17 [53]. IL-2 and IL-15 all could upregulate the expression of Foxp3 by activating STAT5, thus promote the differentiation of Treg cells [54]. In addition, IL-15 could inhibit the differentiation of Th17 by reducing the secretion of IL-17 [55]. In addition to inflammation cytokines, HIF-1α could promote Th17 differentiation by directly inducing ROReγt transcription as well. HIF-1α inhibits Treg differentiation through an active process that targets Foxp3 protein for degradation [42] (Table 1).

5.3. Bile Acid Metabolites. Bile acids (BAs) are natural surfactants derived from cholesterol that is produced in the liver and secreted into the duodenum. BAs play a significant role in lipid digestion, antibacterial defense, and glucose metabolism [56]. Through enterohepatic circulation, bacteria
concentrations of secondary bile acids have immunomodulatory effects [57]. BAs have emerged as modulators of innate immunity and gut inflammation [58]. Compared with that of healthy people, the decrease in the abundance of Firmicum in IBD patients leads to a reduction in the level of secondary bile acids, which weakens the anti-inflammatory effect of secondary bile acids and delays the resolution of inflammation [59]. Studies have shown that the expression of bile acid transporter (ASBT) is decreased in TNBS-induced colitis rats and rabbit models of intestinal inflammation [60]. A recent study reported that bile acids control Th17 cell functions by modulating RORγt activity [61]. Farnesoid-X-receptor (FXR) and transmembrane G protein-coupled receptor 5 (TGR5), the bile acid receptors, regulate innate immunity and the Th17/Treg balance [62, 63]. FXR expression in the inflammatory tissue of Crohn’s disease patients was decreased [64]. Clinical observation of using FXR agonist to stimulate IBD patients showed that the secretion of proinflammatory cytokines IL-17, IFN-γ, and TNF in lamina propria mononuclear cells was significantly decreased [65]. TGR5 activation of macrophages, which was cocultured with CD4^+ T cells, inhibited the release of IL-17 in the culture supernatant [66]. FXR and TGR5 agonists may be used to treat IBD (Figure 1).

5.4. The Intestinal Microbiota. There are many microorganisms in the gastrointestinal tract that are near related to human health. With the in-depth study of the intestinal microbiota, it has been found that the incidence of IBD is closely related to intestinal microbiota imbalance. Chu et al. [63] noted that intestinal microbiota dysbiosis is the leading cause of immune imbalance and intestinal diseases such as IBD.

Studies have shown that the intestinal microbiota and its metabolites can affect Th17/Treg differentiation. A recent study showed that the microorganisms of humans with IBD could affect the balance of gut Th17 and RORγt^+ Treg cells in mice [67]. By using GF mice and antibiotic treatment models, various researchers have found that colonic Th17 cells and Treg cells are significantly decreased in GF mice [68, 69]. Recently, it has been found that ATP and SCFAs, the metabolites derived from the intestinal microbiota, respectively, stimulate the differentiation of Th17 cells and Treg cells [70, 71].

Intestinal microbes and their bacterial products directly act on TLRs and other innate immune receptors to mediate Th17 cell differentiation. A study showed that in the presence of TLR9, intestinal flora DNA can directly induce and promote the differentiation of Th17 cells, inhibit Treg cells, and exacerbate intestinal inflammation [72]. In addition, apoptotic intestinal epithelial cells infected with bacteria also provide ligands for TLRs and activate dendritic cells to secrete IL-6 and TGF-β, leading to increased Th17 cell differentiation [73]. The specific role of each TLR in Th17 cell differentiation induction remains to be further explored. One type of filamentous bacteria, segmented filamentous bacteria (SFB), induced naive CD4^+ T cells to differentiate into Th17 cells. Many kinds of research have shown that SFB promotes the differentiation of Th17 cells through serum amyloid A protein (SAA) and dendritic cells (DCs) in intestinal epithelial cells. The cytokine IL-23 secreted by DCs, in turn, can promote an increase in SAA and enhance the secretion of IL-17, thus enhancing the differentiation of Th17 cells and maintaining the intestinal inflammation [74, 75].

Studies on the relationship between the intestinal flora and Treg cells have mostly focused on short-chain fatty acids (SCFAs) and Treg cells. SCFAs can act on intestinal epithelial mucosal cells through TGF-β1 to facilitate the differentiation of nTreg cells. SCFAs can also inhibit the activity of histone deacetylase in order to make histones highly acetylated, regulate the expression of related genes, produce anti-inflammatory factors, or lead to growth inhibition and the apoptosis of associated cells, which generates immune tolerance [76]. SCFAs can also affect the ATP level via G protein-coupled receptors (GPCRs) (such as GPR43) or mammalian target of rapamycin (mTOR), thereby influencing the differentiation of Treg cells [77]. In addition, some intestinal flora has been found to alter the Th17/Treg cell balance towards Treg cells by releasing polysaccharide A (PSA);

![Figure 1: The role of bile acid and bile acid receptor FXR/TGR5 agonist in Th17/Treg balance.](image)
Bacteroides fragilis upregulates Foxp3 expression and promotes Treg cell differentiation. Clostridium IV and the XIV flora also induce Foxp3 expression and Treg cell differentiation [78].

A study showed that probiotics could reduce the secretion of TNF-α and IL-23 in the serum of mice with oxazolidone-induced colitis. IL-23 is a crucial factor in maintaining the survival, proliferation, and stability of Th17 cells. Therefore, probiotics can inhibit the production and function of IL-17 by reducing the secretion of IL-23, which confirms that probiotics can improve intestinal inflammation in this way [79]. Studies have shown that probiotic B. adolescentis can transmit probiotic-mediated adaptive immune regulation to the Treg/Th17 axis through the trl2/ERK/MAPK/NF-κB signaling pathway, stimulate immunosuppressive polarization of macrophages, and secrete the cytokine IL-10 [16]. Probiotics may be used in the treatment of IBD (Figure 2).

6. Conclusions

The imbalance of Th17/Treg cells is a vital factor, which influences the occurrence and development of IBD. Th17 cells promote the occurrence of intestinal inflammation and induce autoimmune diseases, while Treg cells inhibit intestinal inflammation. The balance is mainly affected by TCR signaling, costimulatory signals, cytokines, bile acid metabolites, intestinal microbiomes, and other factors. The study of the mutual transformational mechanism of Th17/Treg cells has deepened the understanding of the immune mechanisms of IBD and may provide new research directions of IBD in the future.

Data Availability

All data generated or analyzed during this study are included in this article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This study was supported by the Zhejiang Provincial Natural Science Foundation of China (Grant No. LY17H290007), the Research Project of the Health Commission of Zhejiang Province (Grant No. 2018KY550), the Research Project of Zhejiang Traditional Chinese Medicine Administration (CN) (Grant No. 2020ZB081), and Research Project of Zhejiang Chinese Medical University (No. 2019ZG03) and the Zhejiang Provincial Key Lab of Diagnosis and Treatment of Circulatory Diseases (Grant No. 2019E10012).

References

[1] N. A. Molodecky, I. S. Soon, D. M. Rabi et al., “Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review,” Gastroenterology, vol. 142, no. 1, pp. 46–54.e42, 2012.
[2] A. N. Ananthakrishnan, “Epidemiology and risk factors for IBD,” Nature Reviews Gastroenterology & Hepatology, vol. 12, no. 4, pp. 205–217, 2015.
[3] A. N. Ananthakrishnan, C. N. Bernstein, D. Iliopoulos et al., “Environmental triggers in IBD: a review of progress and evidence,” Nature Reviews Gastroenterology & Hepatology, vol. 15, no. 1, pp. 39–49, 2018.
[4] G. Iacomino, V. Rotondi Auﬁero, N. Iannaccone et al., “IBD: role of intestinal compartments in the mucosal immune response,” Immunobiology, vol. 225, no. 1, article 151849, 2020.
[5] F. A. Silva, B. L. Rodrigues, M. L. Ayarizono, and R. F. Leal, “The immunological basis of inflammatory bowel disease,” Gastroenterology research and practice, vol. 2016, Article ID 2097274, 11 pages, 2016.
[6] M. A. Daniels and E. Teixeiro, “TCR signaling in T cell memory,” *Frontiers in Immunology*, vol. 6, 2015.

[7] A. Ueno, L. Jeffery, T. Kobayashi, T. Hibi, S. Ghosh, and H. Jijon, “Th17 plasticity and relevance to inflammatory bowel disease,” *Journal of Autoimmunity*, vol. 87, pp. 38–49, 2018.

[8] J. Gálvez, “Role of Th17 cells in the pathogenesis of human IBD,” *ISRN inflammation*, vol. 2014, Article ID 928461, 14 pages, 2014.

[9] C. G. Mayne and C. B. Williams, “Induced and natural regulatory T cells in the development of inflammatory bowel disease,” *Inflammatory Bowel Diseases*, vol. 19, no. 8, pp. 1772–1788, 2013.

[10] E. M. Shevach and A. M. Thornton, “iTregs, piTregs, and iTregs: similarities and differences,” *Immunological Reviews*, vol. 259, no. 1, pp. 88–102, 2014.

[11] K. Singh, M. Hjort, L. Thorvaldson, and S. Sandler, “Concomitant analysis of Helios and Neuropilin-1 as a marker to detect thymic derived regulatory T cells in naive mice,” *Scientific Reports*, vol. 5, no. 1, 2015.

[12] E. Bettelli, Y. Carrier, W. Gao et al., “Reciprocal developmental pathways for the generation of pathogenic effector T<sub>eff</sub>17 and regulatory T cells,” *Nature*, vol. 441, no. 7090, pp. 235–238, 2006.

[13] M. Veldhoen, R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger, “TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells,” *Immunity*, vol. 24, no. 2, pp. 179–189, 2006.

[14] S. Fujino, A. Andoh, S. Bamba et al., “Increased expression of interleukin 17 in inflammatory bowel disease,” *Gut*, vol. 52, no. 1, pp. 65–70, 2003.

[15] S. Acharya, M. Timilshina, L. Jiang et al., “Amelioration of experimental autoimmune encephalomyelitis and DSS induced colitis by NTG-A-009 through the inhibition of Th1 and Th17 cells differentiation,” *Scientific Reports*, vol. 8, no. 1, 2018.

[16] R. Yu, F. Zuo, H. Ma, and S. Chen, “Exopolysaccharide-producing Bifidobacterium adolescentis strains with similar adhesion property induce differential regulation of inflammatory immune response in Treg/Th17 axis of DSS-colitis mice,” *Nutrients*, vol. 11, no. 4, p. 782, 2019.

[17] T. V. Velikova, L. Mitcheva, N. Stanilov, Z. Spassova, and S. A. Stanilova, “Interleukin-6 compared to the other Th17/Treg related cytokines in inflammatory bowel disease and colorectal cancer,” *World Journal of Gastroenterology*, vol. 26, no. 16, pp. 1912–1925, 2020.

[18] G. Tejón, V. Manriquez, J. de Calisto et al., “Vitamin A impairs the reprogramming of Tregs into IL-17-producing cells during intestinal inflammation,” *BioMed Research International*, vol. 2015, Article ID 137893, 8 pages, 2015.

[19] J. E. Smith-Garvin, G. A. Koretzky, and M. S. Jordan, “T cell activation,” *Annual Review of Immunology*, vol. 27, no. 1, pp. 591–619, 2009.

[20] N. R. Gascoigne, V. Rybakin, O. Acuto, and J. Brzostek, “TCR signal strength and T cell development,” *Annual Review of Cell and Developmental Biology*, vol. 32, no. 1, pp. 327–348, 2016.

[21] H. S. Kim, S. W. Jang, W. Lee et al., “PTEN drives Th17 cell differentiation by preventing IL-2 production,” *The Journal of Experimental Medicine*, vol. 214, no. 11, pp. 3381–3398, 2017.

[22] J. P. Elmore, M. C. McGee, N. F. Nидетz, O. Anannya, W. Huang, and A. August, “Tuning T helper cell differentiation by ITK,” *Biochemical Society Transactions*, vol. 48, no. 1, pp. 179–185, 2020.

[23] S. Tanaka, S. Maeda, M. Hashimoto et al., “Graded attenuation of TCR signaling elicits distinct autoimmune diseases by altering thymic T cell selection and regulatory T cell function,” *Journal of immunology*, vol. 185, no. 4, pp. 2295–2305, 2010.

[24] R. P. Joshi, A. M. Schmidt, J. Das et al., “The ε isoform of diacylglycerol kinase plays a predominant role in regulatory T cell development and TCR-mediated ras signaling,” *Science signaling*, vol. 6, no. 303, 2013.

[25] X. Chen, J. J. Priatet, M. T. Chow, and H. S. Teh, “Preferential development of CD4 and CD8 T regulatory cells in RasGRP1-deficient mice,” *Journal of immunology*, vol. 180, no. 9, pp. 5973–5982, 2008.

[26] M. Schmidt-Supprian, J. Tian, E. P. Grant et al., “Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 13, pp. 4566–4571, 2004.

[27] S. Hwang, K. D. Song, R. Lesourne et al., “Reduced TCR signaling potential impairs negative selection but does not result in autoimmune disease,” *The Journal of Experimental Medicine*, vol. 209, no. 10, pp. 1781–1795, 2012.

[28] R. H. Schwartz, “A cell culture model for T lymphocyte clonal anergy,” *Science*, vol. 248, no. 4961, pp. 1349–1356, 1990.

[29] M. O. Li and A. Y. Rudensky, “T cell receptor signalling in the control of regulatory T cell differentiation and function,” *Nature Reviews Immunology*, vol. 16, no. 4, pp. 220–233, 2016.

[30] L. Yang, S. Chen, Q. Zhao, Y. Sun, and H. Nie, “The critical role of Bach2 in shaping the balance between CD4+ T cell subsets in immune-mediated diseases,” *Mediators of inflammation*, vol. 2019, Article ID 2609737, 9 pages, 2019.

[31] M. Sasikala, V. V. Ravikanth, K. Murali Manohar et al., “Bach2 repression mediates Th17 cell induced inflammation and associates with clinical features of advanced disease in chronic pancreatitis,” *United European Gastroenterology Journal*, vol. 6, no. 2, pp. 272–282, 2018.

[32] I. Vogel, A. Kasran, J. Cremer et al., “CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity,” *European Journal of Immunology*, vol. 45, no. 6, pp. 1832–1841, 2015.

[33] S. Bhattia, M. Edidin, S. C. Almo, and S. G. Nathenson, “Different cell surface oligomeric states of B7-1 and B7-2: implications for signaling,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 43, pp. 15569–15574, 2005.

[34] H. Park, Z. Li, X. O. Yang et al., “A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17,” *Nature Immunology*, vol. 6, no. 11, pp. 1133–1141, 2005.

[35] J. J. Engelhardt, T. J. Sullivan, and J. P. Allison, “A cell culture model for T lymphocyte clonal anergy,” *Nature Reviews Immunology*, vol. 17, no. 6, pp. 591–596, 2017.

[36] N. R. Gascoigne, V. Rybakin, O. Acuto, and J. Brzostek, “TCR signal strength and T cell development,” *Annual Review of Cell and Developmental Biology*, vol. 32, no. 1, pp. 327–348, 2016.

[37] H. S. Kim, S. W. Jang, W. Lee et al., “PTEN drives Th17 cell differentiation by preventing IL-2 production,” *The Journal of Experimental Medicine*, vol. 214, no. 11, pp. 3381–3398, 2017.
phase of crescentic glomerulonephritis,” *Nephrology Dialysis Transplantation*, vol. 34, no. 3, pp. 429–441, 2019.

[38] M. F. Krummel and J. P. Allison, “CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation,” *The Journal of Experimental Medicine*, vol. 182, no. 2, pp. 459–465, 1995.

[39] N. Manel, D. Unutmaz, and D. R. Littman, “The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt,” *Nature Immunology*, vol. 9, no. 6, pp. 641–649, 2008.

[40] L. Duranton, W. T. Watford, H. L. Ramos et al., “Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis,” *Immunity*, vol. 32, no. 5, pp. 605–615, 2010.

[41] M. Boirivant, F. Pallone, C. di Giacinto et al., “Inhibition of Sma/d7 with a specific antisense oligonucleotide facilitates TGF-β1-mediated suppression of colitis,” *Gastroenterology*, vol. 131, no. 6, pp. 1786–1798, 2006.

[42] E. V. Dang, J. Barbi, H. Y. Yang et al., “Control of T(H)17/Treg balance by hypoxia-inducible factor 1,” *Cell*, vol. 146, no. 5, pp. 772–784, 2011.

[43] S. Sedda, I. Marafini, V. Dinallo, D. di Fusco, and G. Monteleone, “The TGF-β/Smad system in IBD pathogenesis,” *Inflammatory Bowel Diseases*, vol. 21, no. 12, pp. 2921–2925, 2015.

[44] C. L. Langrish, Y. Chen, W. M. Blumenschein et al., “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation,” *The Journal of Experimental Medicine*, vol. 201, no. 2, pp. 233–240, 2005.

[45] M. Kanamori, H. Nakatsukasa, M. Okada, Q. Lu, and A. Yoshimura, “Induced regulatory T cells’ development, stability, and applications,” *Trends in Immunology*, vol. 37, no. 11, pp. 803–811, 2016.

[46] S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono, “Regulatory T cells and immune tolerance,” *Cell*, vol. 133, no. 5, pp. 775–787, 2008.

[47] I. Ivanov, B. S. McKenzie, L. Zhou et al., “The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells,” *Cell*, vol. 126, no. 6, pp. 1121–1133, 2006.

[48] C. Parham, M. Chirica, J. Timans et al., “A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R,” *Journal of Immunology*, vol. 168, no. 11, pp. 5699–5708, 2002.

[49] M. W. Teng, E. P. Bowman, J. J. McElwee et al., “IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases,” *Nature Medicine*, vol. 21, no. 7, pp. 719–729, 2015.

[50] P. A. Dawson and S. J. Karpen, “Intestinal transport and metabolism of bile acids,” *Journal of Lipid Research*, vol. 56, no. 6, pp. 1085–1099, 2015.

[51] L. Zhou, J. E. Lopes, M. M. Chong et al., “TGF-β-induced Foxp3 inhibits Th17 cell differentiation by antagonizing RORγt function,” *Nature*, vol. 453, no. 7192, pp. 236–240, 2008.

[52] T. J. Harris, J. F. Grosso, H. R. Yen et al., “Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity,” *Journal of Immunology*, vol. 179, no. 7, pp. 4313–4317, 2007.

[53] Q. Dai, Y. Li, H. Yu, and X. Wang, “Suppression of Th1 and Th17 responses and induction of Treg responses by IL-18-expressing plasmid gene combined with IL-4 on collagen-induced arthritis,” *BioMed research international*, vol. 2018, Article ID 5164715, 8 pages, 2018.

[54] W. Liao, J. X. Lin, and W. J. Leonard, “Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy,” *Immunity*, vol. 38, no. 1, pp. 13–25, 2013.

[55] C. Apert, P. Romagnoli, and J. P. M. Van Meerwijk, “IL-2 and IL-15 dependent thymic development of Foxp3-expressing regulatory T lymphocytes,” *Protein & Cell*, vol. 9, no. 4, pp. 322–332, 2018.

[56] J. M. Ridlon, D. J. Kang, and P. B. Hylomen, “Bile salt biotransformations by human intestinal bacteria,” *Journal of Lipid Research*, vol. 47, no. 2, pp. 241–259, 2006.

[57] W. Jia, G. Xie, and W. Jia, “Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis,” *Nature Reviews Gastroenterology & Hepatology*, vol. 15, no. 2, pp. 111–128, 2018.

[58] H. Duboc, S. Rajca, D. Rainteau et al., “Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases,” *Gut*, vol. 62, no. 4, pp. 531–539, 2013.

[59] L. R. Fitzpatrick and P. Jenabzadeh, “IBD and bile acid absorption: focus on pre-clinical and clinical observations,” *Frontiers in Physiology*, vol. 11, 2020.

[60] S. Hang, D. Paik, L. Y. Yao et al., “Bile acid metabolites control T(H)17 and T(reg) cell differentiation,” *Nature*, vol. 576, no. 7785, pp. 143–148, 2019.

[61] L. Ding, L. Yang, Z. Wang, and W. Huang, “Bile acid nuclear receptor FXR and digestive system diseases,” *Acta Pharmacologica Sinica B*, vol. 5, no. 2, pp. 135–144, 2015.

[62] S. Fiorucci, M. Biagioli, A. Zampella, and E. Distrutti, “Bile acids activated receptors regulate innate immunity,” *Frontiers in Immunology*, vol. 9, 2018.

[63] H. Chu, A. Khosravi, I. P. Kusumawardhani et al., “Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease,” *Science*, vol. 352, no. 6289, pp. 1116–1120, 2016.

[64] P. Vavassori, A. Mencarelli, B. Renga, E. Distrutti, and S. Fiorucci, “The bile acid receptor FXR is a modulator of intestinal innate immunity,” *Journal of Immunology*, vol. 183, no. 10, pp. 6251–6261, 2009.

[65] R. M. Gadalaeta, K. J. van Erpecum, B. Oldenburg et al., “Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease,” *Gut*, vol. 60, no. 4, pp. 463–472, 2011.

[66] J. Yang, J. Hu, L. Feng et al., “Decreased expression of TGR5 in Vogt-Koyanagi-Harada (VKH) disease,” *Ocular Immunology and Inflammation*, vol. 28, no. 2, pp. 200–208, 2020.

[67] G. J. Britton, E. J. Contijoch, I. Mogno et al., “Microbiotas from humans with inflammatory bowel disease alter the balance of gut TH17 and RORγt regulatory T cells and exacerbate colitis in mice,” *Immunity*, vol. 50, no. 1, pp. 212–24.e4, 2019.

[68] Y. Mishima, B. Liu, J. J. Hansen, and R. B. Sartor, “Resident bacteria-stimulated IL-10-secreting B cells ameliorate T cell-mediated colitis by inducing Tr-1 cells that require IL-27-signaling,” *Cellular and Molecular Gastroenterology and Hepatology*, vol. 1, no. 3, pp. 295–310, 2015.

[69] K. M. Telesford, W. Yan, J. Ochoa-Reparaz et al., “A commensal symbiotic factor derived from *Bacteroides fragilis* promotes human CD39+Foxp3+ T cells and Treg function,” *Gut Microbes*, vol. 6, no. 4, pp. 234–242, 2015.
[70] C. B. Larmonier, K. W. Shehab, F. K. Ghishan, and P. R. Kiela, “T lymphocyte dynamics in inflammatory bowel diseases: role of the microbiome,” BioMed research international, vol. 2015, Article ID 504638, 9 pages, 2015.

[71] P. M. Smith, M. R. Howitt, N. Panikov et al., “The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis,” Science, vol. 341, no. 6145, pp. 569–573, 2013.

[72] P. Hemarajata and J. Versalovic, “Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation,” Therapeutic Advances in Gastroenterology, vol. 6, no. 1, pp. 39–51, 2013.

[73] R. Rogier, M. I. Koenders, and S. Abdollahi-Roodsaz, “Toll-like receptor mediated modulation of T cell response by commensal intestinal microbiota as a trigger for autoimmune arthritis,” Journal of immunology research, vol. 2015, Article ID 527696, 8 pages, 2015.

[74] I. Ivanov, K. Atarashi, N. Manel et al., “Induction of intestinal Th17 cells by segmented filamentous bacteria,” Cell, vol. 139, no. 3, pp. 485–498, 2009.

[75] Y. Goto, C. Panea, G. Nakato et al., “Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation,” Immunity, vol. 40, no. 4, pp. 594–607, 2014.

[76] D. Parada Venegas, M. K. de la Fuente, G. Landskron et al., “Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases,” Frontiers in Immunology, vol. 10, 2019.

[77] A. Luo, S. T. Leach, R. Barres, L. B. Hesson, M. C. Grimm, and D. Simar, “The microbiota and epigenetic regulation of T helper 17/regulatory T cells: in search of a balanced immune system,” Frontiers in Immunology, vol. 8, 2017.

[78] S. Omenetti and T. T. Pizarro, “The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome,” Frontiers in Immunology, vol. 6, 2015.

[79] K. Wang, H. Dong, Y. Qi et al., “Lactobacillus casei regulates differentiation of Th17/Treg cells to reduce intestinal inflammation in mice,” Journal of Veterinary Research, vol. 81, no. 2, pp. 122–128, 2017.